All In Biotech

Drug Trial Radar · NCT06912633

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

A Randomized, Masked, Sham-Controlled Phase 2 Trial of the Safety of a Single Intravitreal Injection of jCell (Famzeretcel) for the Treatment of Retinitis Pigmentosa (RP)

Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

31

Actual

Start

Jun 20, 2025

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
jCyte, IncIndustry
Sponsor type
Industry
First posted
Apr 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety of a single injection of jCell (famzeretcel) comprising 6.0 million (6.0M) retinal progenitor cells over a six-month study period in a cohort of adult subjects with RP. Additionally, changes in visual function will be evaluated at six months between the active treatment group (6.0M jCell) compared to sham-treated controls.

Conditions

  • Retinitis Pigmentosa

Interventions

  • human retinal progenitor cellsBiological

    Single intravitreal injection of 6.0 million retinal progenitor cells (RPCs)

  • Mock injectionOther

    Pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection. Subjects randomized to the sham control group will undergo identical preparation as the active treatment group immediately prior to treatment, including application of anesthetics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of Intravitreal Injection of 6.0M jCellTime frame: 6 months

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Associated Retina Consultants

    Phoenix, Arizona

  • California Retina Consultants

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Gavin Herbert Eye Institute, UC Irvine

    Irvine, California

  • Retina Consultants Medical Group

    Sacramento, California

  • Vitreo Retinal Associates

    Gainesville, Florida

  • Illinois Retina Associates

    Oak Park, Illinois

  • NJRetina

    Teaneck, New Jersey

  • Long Island Vitreoretinal Consultants

    Westbury, New York

  • Retina Consultants of Texas: Bellaire Retina Center

    Bellaire, Texas

  • Retina Consultants of Texas: San Antonio

    San Antonio, Texas

  • The Retina Group of Washington

    Fairfax, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.